Monte Rosa Therapeutics (GLUE) Prepaid Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Prepaid Assets of $6.7 million for Q1 2026, up 40.02% year-over-year from $4.8 million in Q1 2025, and up 49.92% quarter-over-quarter from $4.5 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Prepaid Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Prepaid Assets history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 40.02% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 40.02% YoY), while the FY2025 annual figure was $4.5 million, down 12.45% from the prior year.
- Prepaid Assets for Q1 2026 stood at $6.7 million, up from $4.5 million in the prior quarter.
- The five-year high for Prepaid Assets was $8.4 million in Q3 2024, with the low at $2.9 million in Q2 2022.
- The 5-year median for Prepaid Assets is $4.8 million (2025), against an average of $5.0 million.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets jumped 135.96% in 2022, then slumped 33.61% in 2025.
- Monte Rosa Therapeutics' Prepaid Assets stood at $4.4 million in 2022, then declined by 25.88% to $3.3 million in 2023, then soared by 55.37% to $5.1 million in 2024, then decreased by 12.45% to $4.5 million in 2025, then soared by 49.92% to $6.7 million in 2026.
- Business Quant data shows GLUE's Prepaid Assets at $6.7 million in Q1 2026, $4.5 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.38 Mn |
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 5.12 Mn |
| Sep 30, 2024 | 8.43 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 3.29 Mn |
| Sep 30, 2023 | 4.14 Mn |
| Jun 30, 2023 | 3.88 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 4.44 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 3.20 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 3.49 Mn |